Skip to main content
Fig. 2 | The Journal of Headache and Pain

Fig. 2

From: An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study

Fig. 2

Mean (SD) change from baseline in all MSQ dimensions. a) Mean role-function restrictive score at baseline was 36.2 (17.8); b) mean role-function preventive score at baseline was 50.2 (22.8); c) mean role-function emotional score at baseline was 42.4 (25.6; P < 0.001). All dimensions evaluated at administration visit 2 through administration visit 8. MSQ = Migraine-Specific Quality-of-Life Questionnaire. *P < 0.001 Wilcoxon signed rank test for change versus baseline (level of significance, 5%). The numbers of patients in administration (Admin) visits 9–13 in all dimensions were as follows: Admin 9, n = 117; Admin 10, n = 50; Admin 11, n = 23; Admin 12, n = 13; Admin 13, n = 6. Mean changes from baseline for the restrictive and preventive scores Admin visits 9–13 were each significant (Admin 9–12, P < 0.001; Admin 13, P = 0.031). Mean changes from baseline for the emotional score Admin visits 9–13 were each significant (Admin 9–11, P < 0.001; Admin 12, P = 0.010; Admin 13, P = 0.031)

Back to article page